Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,686 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 2,686 shares of Relay Therapeutics stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $22,696.70. Following the completion of the sale, the insider directly owned 420,047 shares in the company, valued at $3,549,397.15. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Relay Therapeutics Stock Up 0.8%

NASDAQ RLAY traded up $0.06 during trading on Thursday, hitting $7.71. 1,788,553 shares of the stock traded hands, compared to its average volume of 2,246,533. The firm has a 50-day simple moving average of $7.93 and a 200-day simple moving average of $5.93. Relay Therapeutics, Inc. has a 12-month low of $1.77 and a 12-month high of $9.04. The company has a market capitalization of $1.34 billion, a P/E ratio of -4.41 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). As a group, research analysts predict that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Trading of Relay Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC lifted its position in Relay Therapeutics by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock valued at $34,000 after purchasing an additional 5,000 shares during the period. Quinn Opportunity Partners LLC acquired a new stake in shares of Relay Therapeutics during the 2nd quarter worth approximately $35,000. May Hill Capital LLC purchased a new position in shares of Relay Therapeutics during the 2nd quarter valued at approximately $38,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at $39,000. Finally, Quadrant Capital Group LLC boosted its holdings in Relay Therapeutics by 245.1% during the second quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock worth $41,000 after buying an additional 8,374 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Key Relay Therapeutics News

Here are the key news stories impacting Relay Therapeutics this week:

• Neutral Sentiment: AAII published an explainer on why RLAY slid ~5.18%, summarizing market reaction and citing recent insider transactions as a driver. AAII Article
• Negative Sentiment: CFO Thomas Catinazzo sold 15,515 shares across Jan. 27–28 (13,820 shares at $7.62 and 1,695 at $8.45), totaling roughly $119k + $14k ≈ $120k in disclosed sales; ownership fell ~5.22% then 0.68%. SEC filing: Catinazzo SEC Filing
• Negative Sentiment: Insider Peter Rahmer sold 13,038 shares across Jan. 27–28 (11,684 at $7.62 and 1,354 at $8.45), about $89k + $11.4k ≈ $100k in sales; his holding decreased ~4.03% then 0.49%. SEC filing: Rahmer SEC Filing
• Negative Sentiment: Insider Donald A. Bergstrom sold 21,581 shares across Jan. 27–28 (18,895 at $7.62 and 2,686 at $8.45), about $144k + $22.7k ≈ $167k in sales; his stake fell ~4.28% then 0.64%. SEC filing: Bergstrom SEC Filing

Wall Street Analyst Weigh In

RLAY has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Oppenheimer upgraded shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a report on Monday. Finally, Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $6.00 to $13.00 in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.